Live Glenmark Pharmaceuticals Share Price Chart

O 1044

H 1044

L 1044

VOL 542

Glenmark Pharmaceuticals Performance

Days Range

Low: ₹1,040.10
High: ₹1,063.95
Previous Close ₹1,044.00
Open ₹1,044.00
Volume 4,25,472
Day’s Range ₹1,040.10 - ₹1,063.95
52W Range ₹487.50 - ₹1,070.00
Market Cap ₹29,468 Cr

Glenmark Pharmaceuticals Fundamentals

ROCE (TTM) 9.72
P/E Ratio (TTM) -41.41
P/B Ratio 3.16
Industry P/E 36.29
Debt to Equity 0.56
ROE 6.48
EPS (TTM) 2.2
Dividend Yield 0.24
Book Value 330.53
Face Value 1

Glenmark Pharmaceuticals Financials

Mar 2023Jun 2023Sep 2023Dec 2023
Net Sales3,373.723,036.073,207.382,506.7
Profit before tax-490.77151.4-124.35-521.38
Operating Profit-403.14173.13-61.56-330.82
Net Profit-403.14173.13-61.56-330.82
EPS in Rs14.936.9112.43-9.56

About Glenmark Pharmaceuticals

History of Glenmark Pharmaceuticals Limited

Founded in 1977, Glenmark Pharmaceuticals Limited is a leading global pharmaceutical company. The company’s generics business services meet the requirements of developed markets like the US and Western Europe. Their Active Pharmaceutical Ingredient (API) business sells products in more than 65 countries, such as the US, South America, India, etc.

In 1979, the company forayed into the Dermatology therapy area with their popular brand “Candid Cream”. In 1980, they started operations in Russia and the Commonwealth of Independent States (CIS). Later, in 1983, the company set up their first manufacturing unit in Nashik. In 1999, they set up their first Research and Development (R&D) centre at Sinnar. In the next year, i.e., in 2000, the company released its IPO and got listed on BSE and NSE.

After the listing, the company opened several manufacturing facilities. In 2006, they debuted in the Oncology segment. In 2019, the company’s API arm was split as Glenmark Life Sciences (GLS) and went public in 2021.

As of March 2023, the company has a commercial presence across more than 80 countries in the world. They have more than 50 offices, 18 state-of-the-art manufacturing facilities, 8 manufacturing facilities approved by the U.S. FDA and 4 R&D centres. The product portfolio of the company includes Complex Injectables and Biologics, Oral Solids, Liquids, Topical Products and Respiratory MDI/DP.

Business Segments of Glenmark Pharmaceuticals Limited 

  • Research and Development: This segment primarily focuses on therapeutic areas, such as Respiratory, Dermatology and Oncology.
  • Formulations: Under this segment, the company works towards developing branded and generic formulations. They work towards developing products across respiratory, dermatology and cardio-metabolic therapy areas. They develop innovative products for markets, including Russia and CIS, India, Brazil, Africa and Asia.
  • Active Pharmaceutical Ingredients (API): Under this segment, the company manufactures a wide range of high-quality APIs for customers globally. They focus on therapeutic areas, such as Cardiovascular, Central Nervous System, Pain Management, Diabetes, Anti-acne, Urinary anti-spasmodic, Diuretic, Anti-arhythmic, Anti-coagulant, Anti-fungal, Anti-viral, etc. Under this, the company works with the 20 largest generic pharmaceutical companies in the world. They have 77 patents.

As of March 31, 2023, a few of the subsidiaries of Glenmark Pharmaceuticals Limited are:

  • Glenmark Pharmaceuticals Inc.: This is a wholly-owned subsidiary of the company that looks after its operations in the USA.
  • Glenmark Life Sciences Limited: This subsidiary of the company is publicly listed and carries out API manufacturing.
  • Ichnos Sciences Inc.: This subsidiary of the company focuses on innovation in biologics.

Key Personalities of Glenmark Pharmaceuticals Limited

Glenn Saldanha, Chairman and Managing Director

Glenn Saldanha has been the CEO and Managing Director of Glenmark Pharmaceuticals Limited since 2000. He joined the company in 1998. Under his guidance, the company was transformed into a truly multinational company and has evolved from an Indian branded generics business into a research-driven and innovation-led organisation. Glenmark also won the ‘Indian Pharma Innovation of the Year’ award by the Government of India.

Parent Organisation Indian Private
Founded 1977
Managing Director Glenn Saldanha

Peer Comparison

Stocks Market Cap (cr) Market Price (₹) 52 Week Low-High (₹)
Lupin Ltd ₹73,290.95


6.80 (0.42%)

1600.1 - 1636.95View Peer Comparison
Gland Pharma Ltd ₹28,843.28


2.55 (-0.15%)

1731.7 - 1768.5View Peer Comparison
Syngene International Ltd ₹29,089.81


13.25 (-1.83%)

703.55 - 722.95View Peer Comparison
Alkem Laboratories Ltd ₹56,301.96


18.65 (0.40%)

4680 - 4775.95View Peer Comparison
Glaxosmithkline Pharmaceuticals Ltd ₹32,234.58


10.20 (-0.54%)

1877.75 - 1914View Peer Comparison

What's Trending

Glenmark Pharmaceuticals FAQs

What is the Share price of Glenmark Pharmaceuticals (GLENMARK)?

Glenmark Pharmaceuticals (GLENMARK) share price as of April 16, 2024, on NSE is Rs 1,060.00 (NSE) and Rs 1,059.05 (BSE) on BSE.

Can I buy Glenmark Pharmaceuticals (GLENMARK) shares?

Yes, You can buy Glenmark Pharmaceuticals (GLENMARK) shares by opening a Demat account with Angel One.

How do I buy Glenmark Pharmaceuticals (GLENMARK) from Angel One?

Glenmark Pharmaceuticals (GLENMARK) share can be brought through the following modes:
  1. Direct investment: You can buy Glenmark Pharmaceuticals (GLENMARK) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Glenmark Pharmaceuticals (GLENMARK) shares.

What is the main business of Glenmark Pharmaceuticals?

Glenmark Pharmaceuticals Ltd focuses on the discovery and development of new chemical entities (NCEs). It develops and markets branded and generic formulations. The company’s formulation business encompasses therapeutic areas such as dermatology, respiratory, and oncology.

Who are the promoters of Glenmark Pharmaceuticals?

Saldanha Family Trust is the promoter of Glenmark Pharmaceuticals.

What are the Subsidiaries that comes under Glenmark Pharmaceuticals?

Glenmark Holding SA La Chaux-de-Fonds., Glenmark Dominicana SRL., Glenmark Pharmaceuticals Egypt S.A.E., Glenmark Pharmaceuticals Colombia SAS, Colombia., Glenmark Pharmaceuticals FZE., Glenmark Pharmaceuticals (Australia) Pty Ltd., Glenmark Pharmaceuticals Kenya Ltd. are few of the subsidiaries that comes under Glenmark Pharmaceuticals